Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Appili Therapeutics Inc. (APLIF : OTC)

• Company Description    Appili Therapeutics Inc. is a biopharmaceutical company. It acquires, develops and commercializes novel medicines for unmet needs in the infectious disease. The company's lead product consist ATI-2307, ATI-1501 and ATI-1701 which are in clinical stage. Appili Therapeutics Inc. is based in Halifax, Canada. Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $0.01 Daily Weekly Monthly 20 Day Moving Average: 23,639 shares Shares Outstanding: 121.27 (millions) Market Capitalization: $1.21 (millions) Beta: -0.59 52 Week High: $0.03 52 Week Low: $0.01 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -21.88% -23.28% 12 Week -5.66% -14.35% Year To Date -64.29% -68.11%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 21-1344 SUMMER ST. - HALIFAX,A5 B3H 0A8 CAN ph: 902-442-4655 fax: - None http://www.appilitherapeutics.com

• General Corporate Information    Officers Don Cilla - President and Chief Executive Officer Armand Balboni - Chairman Kenneth Howling - Acting Chief Financial Officer Art Baran - Director Carl Gelhaus - Director Peer Information Appili Therapeutics Inc. (CORR.) Appili Therapeutics Inc. (RSPI) Appili Therapeutics Inc. (CGXP) Appili Therapeutics Inc. (BGEN) Appili Therapeutics Inc. (GTBP) Appili Therapeutics Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 03783R107 SIC: 2834 Fiscal Year Fiscal Year End: March Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/13/25 Share - Related Items Shares Outstanding: 121.27 Most Recent Split Date: (:1) Beta: -0.59 Market Capitalization: $1.21 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 0.00% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -78.37% vs. Previous Quarter: 2,466.67% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - -107.24 03/31/25 - -118.77 12/31/24 - -203.73 Current Ratio 06/30/25 - 0.12 03/31/25 - 0.19 12/31/24 - 0.14 Quick Ratio 06/30/25 - 0.12 03/31/25 - 0.19 12/31/24 - 0.14 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - -2,072.73 03/31/25 - -2,593.67 12/31/24 - - Book Value 06/30/25 - -0.09 03/31/25 - -0.08 12/31/24 - -0.08 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©